ReviewFrontiers in immunology2023
The potential of regulatory T cell-based therapies for alopecia areata.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double-blind, placebo-controlled, Phase 2 study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Trial
- Distinctive T Cell Patterns Defining Lymphocytic Alopecia and Alternate Autoimmune and Stem Cell Pathways, Linked to Pleiotropic Functions of Regulatory T Cells Within iSALT.The American Journal of dermatopathology · 2026Review
- Hair follicle immune privilege in autoimmune and immune-mediated alopecias: paths toward reestablishing immune tolerance.Frontiers in medicine · 2026Review
- IL-15 in alopecia areata: the immune tolerance mechanistic insights and translational perspectives.Frontiers in medicine · 2026Review
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
- Dermal T cell immunity and key regulatory signaling pathways: Implications in immune-mediated alopecia and hair regeneration.Genes & diseases · 2025Review
- Macrophage-Centric Immunometabolic Crosstalk in Alopecia Areata Pathogenesis: Mechanisms and Therapeutic Implications.Clinical reviews in allergy & immunology · 2025Review
- [CAR-T cells in Dermatology: Mechanisms of action and applications in autoimmune diseases].Revista medica del Instituto Mexicano del Seguro Social · 2025Review
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology.Frontiers in immunology · 2025Review
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches.Frontiers in immunology · 2025Review
- Mini-Review: Tregs as a Tool for Therapy-Obvious and Non-Obvious Challenges and Solutions.Cells · 2024Review
- Immune niches for hair follicle development and homeostasis.Frontiers in physiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytotoxic T lymphocyte has been a concern for the etiopathogenesis of alopecia areata (AA), some recent evidence suggests that the regulatory T (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.